SEC Form 4/A · accession 0000891293-17-000109
CTI BIOPHARMA CORP · CTIC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
David Kirske
Officer — EVP, Chief Financial Officer
Period of report
Aug 31, 2017
Accepted (ET)
Oct 19, 2017 · 4:11 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000891293
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F1,F2 | $3.25 | Aug 31, 2017 | A | 25,000 | A | — | Aug 31, 2027 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1On August 3, 2017, the reporting person filed a Form 4 which inadvertently reported that, on August 1, 2017 (the first day of the reporting person's employment with CTIC), CTIC granted the reporting person an option to purchase 25,000 shares of CTIC Common Stock. In fact, as reported in this amendment, such stock option was not granted until August 31, 2017 (the last day of the month in which the reporting person was first employed by CTIC).
- F2The stock options will vest over a period of one year from the grant date in twelve equal monthly installments. The grant will accelerate and fully vest should Mr. Kirske's employment be terminated by the Company without cause within the first six months after the grant date.